---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-025463"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:18:21.708405+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology Q2 net income $5.9M vs year-ago loss; revenue rises to $52.4M

## Summary
- GAAP EPS $0.12 vs $(0.09) loss; adjusted EPS $0.15 vs $(0.05) loss.
- Net product revenue $49.2M (+11% YoY); total revenue $52.4M (+11% YoY).
- Q3 2025 guidance: net product revenue $46–48M, total revenue $48–51M, net income $2–4M.
- Full-year 2025 revenue outlook reaffirmed at $212–222M; gross-to-net adjustment raised to 21.5–22.0%.
- Cash & equivalents $96M; key milestones: alisertib interim data in Q4 2025 for two Phase II trials.

## SEC filing metadata
- accession: 0001437749-25-025463
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/0001437749-25-025463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/pbyi20250724_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-025463
- JSON: https://secwatch.observer/filing/0001437749-25-025463.json
- Plain text: https://secwatch.observer/filing/0001437749-25-025463.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.